The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
US FDA approval based on NEURO-TTRansform Phase III results
The plant is yet to start commercial operations
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Subscribe To Our Newsletter & Stay Updated
